Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
April 27, 2020 09:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE
April 06, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020
March 17, 2020 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
Incysus Therapeutics Announces Issuance of Foundational U.S. Patent Covering Use of Drug Resistant Immunotherapy (DRI) Technology for the Treatment of Cancer
January 29, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
AB Science annonce la publication de trois résumés d’étude de la molécule AB8939 dans l’édition spéciale de la revue Blood consacré au congrès annuel de 'ASH
December 09, 2019 02:19 ET
|
AB Science
Paris, 9 décembre 2019, 8h30 AB Science annonce la publication de trois résumés d’étudede la molécule AB8939 dans l’édition spéciale de la revue Blood consacréau congrès annuel de...
AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
December 09, 2019 02:19 ET
|
AB Science
Paris, 09 December, 2019, 8.30am AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood AB Science SA (NYSE Euronext - FR0010557264 -...
Incysus Therapeutics to Present at the New York Oncology Investor Conference
November 07, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
AB Science annonce que la molécule AB8939 obtient la désignation de médicament orphelin auprès de la FDA dans le traitement de la leucémie myéloïde aigue
November 07, 2019 02:26 ET
|
AB Science
Paris, 7 novembre 2019, 8h30 La molécule AB8939 obtient la désignation de médicamentorphelin auprès de la FDA dans le traitementde la leucémie myéloïde aigue AB Science SA (NYSE Euronext –...
AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
November 07, 2019 02:26 ET
|
AB Science
Paris, November 7, 2019, 8.30am AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA AB Science SA (NYSE Euronext - FR0010557264 - AB) announces today that the U.S. Food and...
AB Science annonce la première présentation de résultats précliniques de la molécule AB8939 au 61eme congrès annuel de l'American Society of Hematology (ASH)
November 06, 2019 16:21 ET
|
AB Science
Paris, 6 novembre 2019, 22h AB Science annonce la première présentation de résultats précliniquesde la molécule AB8939 au 61eme congrès annuel de l'American Society of Hematology (ASH) AB Science SA...